Pith. sign in

REVIEW 5 major objections 4 minor 109 references

Multi-megabase scale genome interpretation with genetic language models

T0 review · 5 major / 4 minor · reviewed 2026-08-10 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read Phenformer predicts disease risk and mechanistic hypotheses directly from up to 88 million base pairs of an individual's genome sequence.

desk verdict A real engineering advance in sequence-to-phenotype modeling, but the mechanistic-superiority claim is oversold by an evaluation design that needs tightening. read the letter →

arxiv 2501.07737 v1 pith:FXQBK5AR submitted 2025-01-13 q-bio.GN cs.LG

Frederik Träuble , Lachlan Stuart , Andreas Georgiou , Pascal Notin , Arash Mehrjou , Ron Schwessinger , Mathieu Chevalley , Kim Branson
show 4 more authors
Bernhard Schölkopf Cornelia van Duijn Debora Marks Patrick Schwab
This is my paper · ORCID
classification q-bio.GNcs.LG
keywords geneticlanguagemodeldiseaseriskpredictionsequence-to-phenotypeEnformercell-typeattributionpolygenicscoresgenomeinterpretationsubtypes
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

Phenformer is a deep-learning model that takes individual genome sequence as input and predicts both disease risk and candidate mechanisms, following the information flow from DNA to cell-type-specific expression to phenotype. The paper's central claim is that a model using only sequence—through a frozen Enformer backbone that embeds 196-kilobase windows around 512 gene start sites—can produce disease-relevant cell- and tissue-type hypotheses that match published literature better than state-of-the-art methods that additionally require single-cell RNA sequencing data. The paper also claims that ensembling Phenformer with standard polygenic risk scores improves risk prediction accuracy in 86.7% of mixed-ancestry and 96.7% of non-European-ancestry disease/method combinations, with average AUROC gains up to 4.2% and 11.19%. If correct, this would make whole-genome sequence interpretation without experimental perturbation feasible at scale, and would extend risk prediction to more diverse populations.

What carries the argument

The central machinery is the frozen Enformer sequence-to-expression backbone used as a tokenizer, followed by a learned expression-to-phenotype transformer. Each individual is represented by 512 tokens; each token is the 3072-dimensional Enformer embedding of a 196 kb window centered on a gene's transcription start site, which encodes predicted expression and chromatin accessibility across many cell types. A shared projection maps tokens to 512 dimensions, Fourier position encodings supply genomic location, four transformer encoder layers model interactions across loci, and Pooling by Multihead Attention (PMA) collapses the set into a pooled representation for a two-layer disease-risk head. Attribution then works backward: saliency gradients on the input embeddings are used to perturb embeddings, and the same Enformer head translates the perturbation into CAGE-track changes, producing cell-type rankings. The Enformer head thus doubles as the interpretability interface that turns risk predictions into mechanistic hypotheses.

What would settle it

Permute the disease labels and retrain Phenformer; if the cell-type and gene attributions still match literature at the reported F1 levels, the mechanistic signal is inherited from the frozen Enformer embeddings rather than learned from disease status.

Watch

Extended reading notes

Core claim

The core discovery the paper argues for is that an end-to-end model can connect individual genomes to phenotypes by learning a mapping from sequence embeddings to disease risk, and that the intermediate attributions of this mapping recover known biology. Specifically, Phenformer extracts 3072-dimensional embeddings from a frozen Enformer model at 512 transcription-start-site-centered windows (about 88 million base pairs, roughly 3% of the genome), processes them through four transformer encoder layers with Fourier position encodings, pools them with multihead attention, and outputs a disease logit. Interpreting the model with saliency gradients and projecting back through Enformer's CAGE tracks yields per-window and per-cell-type importance rankings. The paper reports that these rankings achieve higher F1 against literature-curated cell-type–disease associations than five existing methods that require both genetic and single-cell RNA-seq data, and that the same model's risk predictions improve PRS ensembles and generalize better to non-European ancestries.

Load-bearing premise

The load-bearing premise is that the frozen Enformer embeddings, computed only around 512 gene start sites, carry enough information about how an individual's genetic variants change expression and chromatin that disease risk and mechanisms can be read off from them.

Editorial extensions

If this is right

  • Ensembling Phenformer with standard PRS methods (Lassosum, LDpred2, PRS-CSx, Pthres, C+T) significantly improves AUROC in 86.7% of disease/method combinations in mixed-ancestry and 96.7% in non-European-ancestry test sets.
  • On the 512-gene windows Phenformer sees, it outperforms PRS methods built on the same windows by up to 5.49% AUROC in mixed ancestry and 14.59% in non-European ancestry.
  • Phenformer's cell- and tissue-type attributions match literature-reported disease associations with higher average F1 than five methods that require single-cell RNA sequencing data in addition to genetics.
  • The model surfaces molecular hypotheses for known but unexplained comorbidities, such as liver involvement in psoriasis and small-intestine/appendix involvement in type 1 diabetes.
  • Individual-level attribution embeddings cluster into subtypes with significantly different comorbidity rates, suggesting that sequence alone can stratify patients by disease mechanism.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • If the central claim holds, whole-genome risk prediction can bypass SNP lists and ancestry-specific LD panels: a frozen expression-model backbone acts as a universal tokenizer, and adding more gene windows should improve both risk and mechanism discovery.
  • A clean test of the mechanism claims would compare Phenformer's attributions against those from a variant-effect-tuned backbone; if literature enrichment persists, the signal is in the phenotype head, and if it disappears, it lives in the frozen embeddings.
  • Because only 3% of the genome (512 immune-associated windows) is used, applying the same architecture to the full set of about 21,725 transcription-start-site windows could reveal whether the non-European portability comes from the sequence-to-expression bottleneck or from the particular gene set chosen.
  • The literature baseline itself is produced by an LLM scoring PubMed abstracts, so part of Phenformer's apparent advantage may reflect shared vocabulary with the text-scoring process; a prospective validation on newly discovered cell-type–disease associations would be stronger evidence.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

5 major / 4 minor

Summary. The manuscript introduces Phenformer, a Transformer model that consumes 512 Enformer-derived embedding tokens centered on 196-kb transcription-start-site windows and predicts disease status for six diseases using UK Biobank whole-genome sequencing data from roughly 150,000 individuals. The authors report three main results: (i) Phenformer's cell-type and tissue attributions for disease match PubMed literature with higher F1 than established methods that additionally use single-cell RNA-seq; (ii) logistic-regression ensembles of Phenformer with five polygenic risk score methods improve held-out AUROC, with larger relative gains in non-European ancestry; and (iii) UMAP/HDBSCAN clustering of individual attributions produces comorbidity-associated disease subtypes. The abstract frames the contribution as multi-megabase-scale, sequence-only genome interpretation that both generates mechanistic hypotheses and improves disease risk prediction.

Significance. If the principal claims hold, this would be a meaningful advance: a sequence-only model with roughly 88 Mb of context that both predicts disease risk and proposes cell-type-level mechanisms would go beyond existing PRS and variant-effect methods. The study has clear strengths: a large WGS cohort, a fixed 60/20/20 split, six diseases, bootstrap uncertainty estimates, ancestry-stratified evaluation, and reliance on public data for the main training resource. The risk-prediction component is the more robust contribution: the reported gains are modest but consistent, and the ensemble comparison is in principle reproducible. However, the headline mechanistic claim currently depends on an unvalidated LLM-generated literature gold standard and on an overlap-restricted baseline design, and the risk comparison is labeled 'whole-genome' even though the PRS baselines are constructed from the same 3% of the genome as Phenformer. The manuscript is a strong candidate for publication after the load-bearing evaluation points are reworked.

major comments (5)
  1. [Baseline methods for cell type identification; Figure 2] The central claim that Phenformer outperforms state-of-the-art methods requiring scRNA-seq is not yet established. The pairwise overlap design and the decision to generate Jagadeesh et al. associations only for T1D, psoriasis, and COPD can systematically favor Phenformer, which emits a fixed set of 21 cell types for all six diseases while baselines may output fewer or different cell types. Please report the full disease-by-cell-type association matrices for every method, evaluate on a common predefined set of cell types rather than only the overlap, provide per-disease F1 with confidence intervals, and state explicitly how differences in the number and granularity of predicted cell types are handled.
  2. [Cell type-disease associations supported by literature] The literature gold standard is generated by Claude Sonnet with no reported validation against human expert labels, and the thresholds used to derive enrichment (at least 5% enrichment; at least 5 abstracts with score >= 4) are hand-set. Since the F1 values in Figure 2a are computed at these single thresholds, small changes in scoring behavior or threshold choice could change the ranking of methods. Please validate the LLM scores on a human-curated sample, report agreement statistics, and provide a threshold sweep or precision-recall analysis to show that the reported ranking is not an artifact of the chosen cutoffs.
  3. [Baselines; Figure 3] The labels 'whole-genome level' in Figure 3a-b and in the Results text are not supported by the Methods, which state that the GWAS and PRS baselines were trained using the 'exact same genomic information as provided to Phenformer' (i.e., SNPs inside the 512 selected windows). These panels therefore compare Phenformer to 3%-restricted PRS, not to genome-wide PRS. Please either add genuine whole-genome PRS baselines or reword the manuscript, including the abstract and figure captions, so that the comparison is described as restricted to the 3% of the genome used by Phenformer.
  4. [Section 4.1 Step 1; Discussion limitation] All Phenformer inputs are frozen Enformer embeddings of 196-kb TSS-centered windows, and the paper itself acknowledges in the Discussion (citing Sasse et al., ref 64) that sequence-to-expression backbones 'perform not particularly well' at variant-induced effect prediction. This is load-bearing because any variant effects not captured by Enformer are invisible to Phenformer for both risk prediction and mechanism attribution. Please include a direct evaluation of the backbone's variant sensitivity in the relevant setting, such as an eQTL/MPRA benchmark on the selected windows, a comparison with an alternative sequence embedding, or an analysis of how many test-set variants actually alter the embeddings; absent such evidence, the mechanistic claims should be explicitly conditional on the backbone's variant-effect sensitivity.
  5. [Gene set selection; Section 4.2 Data] The 512-gene window set is selected using Enformer-predicted CAGE changes in a 100-case/50-control psoriasis cohort and then used for all six diseases. This makes the input choice outcome-dependent for psoriasis and raises the possibility that the favorable psoriasis cell-type results in Figure 2, and any disease-general conclusions, are influenced by the gene selection step. Please report sensitivity of the main results to alternative gene sets (e.g., random gene sets of the same size or disease-specific sets) and clarify whether the 150 individuals used for gene selection overlap with the training set used for Phenformer.
minor comments (4)
  1. [Supplementary Figures S1 and S2] The rendered draft contains uninterpretable '/uni...' glyph strings in Figures S1 and S2; these figure panels should be regenerated before resubmission.
  2. [Section 4.2 Data] The cohort size is given as 150119 in one sentence and 150076 in the next; please clarify whether these are different inclusion criteria and harmonize the wording.
  3. [Model interpretation] The saliency aggregation is restricted to 'true positive samples,' but the threshold that defines a true positive prediction is not specified; please state the operating point used.
  4. [Code availability] The code is promised 'upon publication'; for a computational manuscript of this type, please consider making the code, trained model weights, and exact hyperparameter settings available to reviewers, or at minimum specify all baseline software versions and random seeds in the Methods.

Circularity Check

0 steps flagged · score 0.0 of 10

The paper's risk-prediction core is supervised on held-out labels and its mechanistic attributions are post-hoc interpretations rather than fits renamed as predictions; no load-bearing step reduces to its own inputs by construction.

full rationale

The central derivation chain is not circular. Phenformer's disease-risk predictions are trained against held-out disease labels stratified across a fixed train/validation/test split, so the risk model is an independent supervised model rather than a restatement of its inputs. The gene-subset selection uses Enformer-predicted CAGE changes in a small psoriasis reference cohort, but this is a feature-selection heuristic on the training cohort and does not by itself determine held-out test predictions; the model could fail to learn the outcome. The cell-type attribution pipeline perturbs Enformer embeddings and reads the result back through the same frozen Enformer head, but this is an interpretability procedure that maps gradients to Enformer's expression tracks, not a fitted parameter being renamed as a prediction, and it does not force agreement with the literature gold standard. The literature gold standard and overlap-restricted baseline comparisons are methodological and validation concerns, but they are not circular: the Claude Sonnet scores are external to the model, and the overlap restriction is a stated evaluation choice. Self-citations (e.g., refs 65, 96, 97) appear only in peripheral discussions of ethics and causal interpretation and are not load-bearing premises. The paper itself acknowledges the main substantive risk—that the frozen Enformer backbone was not trained for variant effect prediction (ref 64)—which is a correctness risk, not evidence of circularity. Therefore no step, by the paper's own equations or by self-citation, reduces to its own inputs, and the derivation is self-contained under the stated assumptions.

Assumptions & free parameters 5 free parameters · 5 assumptions · 0 invented entities

The central claims rely on several hand-set choices (gene set, thresholds, model size) and on the validity of the frozen Enformer representation as a proxy for variant effects. The axioms listed are the main premises that must hold for the model to work as described.

free parameters (5)
  • Number of TSS-centered windows (m) = 512
    Chosen for computational feasibility; the full set of 21,725 genes was not feasible due to quadratic attention cost. Determines which 3% of the genome is used.
  • Gene set selection thresholds = log2 fold change >= 0.5 and absolute change >= 0.5, top 512 by relative log2 fold change
    Genes selected using Enformer-predicted expression changes between 100 psoriasis cases and 50 controls. The thresholds and the reference cohort are hand-set and create a selection bias.
  • Cell type enrichment threshold = at least 5% enrichment
    Phenformer cell type-disease associations are called when the enrichment score exceeds 5%, a threshold not derived from theory and used for the F1 comparison.
  • Literature evidence scoring thresholds = fraction of abstracts with score >= 1, plus at least 5 abstracts with score >= 4
    The literature reference uses Claude Sonnet integer scores from -5 to 5; the threshold for calling a literature association is arbitrary.
  • Noise regularization parameters = 10-40% of feature range, optional unit log-normal scaling, tuned per disease
    The amount of noise and whether to apply per-sample scaling is tuned separately for each disease, requiring 4 models per disease; these hyperparameters affect final performance.
assumptions (5)
  • domain assumption Enformer embeddings accurately represent the functional effects of genetic variation on expression and chromatin.
    Phenformer relies entirely on frozen Enformer embeddings as input tokens. The paper cites Sasse et al. (ref 64) showing that Enformer performs 'not particularly well' at variant effect prediction, so this assumption is load-bearing and fragile.
  • domain assumption The 512 gene windows (3% of the genome) contain enough causal variation for the six diseases studied.
    Only TSS-centered windows around 512 immune-associated genes are used; variants outside these windows are invisible to the model. The paper itself lists this as a limitation.
  • domain assumption Disease labels derived from UK Biobank records using the Kuan et al. methodology are accurate for training and evaluation.
    The paper relies on validated phenotypes from primary care, hospital episodes, and self-report; label noise is not quantified.
  • domain assumption The central dogma flow (sequence to expression to phenotype) is a valid modeling structure.
    The architecture orders sequence-to-expression before expression-to-phenotype and imposes this inductive bias. It may miss non-expression mechanisms such as splicing or chromatin structure.
  • domain assumption LLM-based scoring of PubMed abstracts provides a valid gold standard for disease-cell type associations.
    The literature benchmark is generated by Claude Sonnet scoring abstracts; this is an automated approximation of the literature and its own errors are not assessed.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Multi-megabase scale genome interpretation with genetic language models." pith.science (2026). https://pith.science/paper/FXQBK5AR

@misc{pith2026250107737,
  author       = {Pith},
  title        = {Pith review of: Multi-megabase scale genome interpretation with genetic language models},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/FXQBK5AR}},
  note         = {Machine review of arXiv:2501.07737}
}
read the original abstract

Understanding how molecular changes caused by genetic variation drive disease risk is crucial for deciphering disease mechanisms. However, interpreting genome sequences is challenging because of the vast size of the human genome, and because its consequences manifest across a wide range of cells, tissues and scales -- spanning from molecular to whole organism level. Here, we present Phenformer, a multi-scale genetic language model that learns to generate mechanistic hypotheses as to how differences in genome sequence lead to disease-relevant changes in expression across cell types and tissues directly from DNA sequences of up to 88 million base pairs. Using whole genome sequencing data from more than 150 000 individuals, we show that Phenformer generates mechanistic hypotheses about disease-relevant cell and tissue types that match literature better than existing state-of-the-art methods, while using only sequence data. Furthermore, disease risk predictors enriched by Phenformer show improved prediction performance and generalisation to diverse populations. Accurate multi-megabase scale interpretation of whole genomes without additional experimental data enables both a deeper understanding of molecular mechanisms involved in disease and improved disease risk prediction at the level of individuals.

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

109 extracted references · 66 canonical work pages

  1. [1]

    Central dogma of molecular biology.Nature, 227(5258):561–563, 1970

    Francis Crick. Central dogma of molecular biology.Nature, 227(5258):561–563, 1970

    1970

  2. [2]

    Effective gene expression prediction from sequence by integrating long-range interactions

    Žiga Avsec, Vikram Agarwal, Daniel Visentin, Joseph R Ledsam, Agnieszka Grabska- Barwinska, Kyle R Taylor, Yannis Assael, John Jumper, Pushmeet Kohli, and David R Kelley. Effective gene expression prediction from sequence by integrating long-range interactions. Nature Methods, 18(10):1196–1203, 2021

    2021

  3. [3]

    Attention is all you need.Advances in Neural Information Processing Systems, 30, 2017

    Ashish Vaswani, Noam Shazeer, Niki Parmar, Jakob Uszkoreit, Llion Jones, Aidan N Gomez, Łukasz Kaiser, and Illia Polosukhin. Attention is all you need.Advances in Neural Information Processing Systems, 30, 2017

    2017

  4. [4]

    Set transformer: A framework for attention-based permutation-invariant neural networks

    Juho Lee, Yoonho Lee, Jungtaek Kim, Adam Kosiorek, Seungjin Choi, and Yee Whye Teh. Set transformer: A framework for attention-based permutation-invariant neural networks. InInternational Conference on Machine Learning, pages 3744–3753. PMLR, 2019

    2019

  5. [5]

    HyenaDNA: Long-range genomic sequence modeling at single nucleotide resolution

    Eric Nguyen, Michael Poli, Marjan Faizi, Armin Thomas, Callum Birch-Sykes, Michael Wornow, Aman Patel, Clayton Rabideau, Stefano Massaroli, Yoshua Bengio, et al. HyenaDNA: Long-range genomic sequence modeling at single nucleotide resolution. arXiv preprint arXiv:2306.15794, 2023. 18 January 15, 2025 prepublication draft

    arXiv 2023

  6. [6]

    China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up.International Journal of Epidemiology, 40(6): 1652–1666, 2011

    Zhengming Chen, Junshi Chen, Rory Collins, Yu Guo, Richard Peto, Fan Wu, and Liming Li. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up.International Journal of Epidemiology, 40(6): 1652–1666, 2011

    2011

  7. [7]

    UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.PLoS Medicine, 12(3):e1001779, 2015

    Cathie Sudlow, John Gallacher, Naomi Allen, Valerie Beral, Paul Burton, John Danesh, Paul Downey, Paul Elliott, Jane Green, Martin Landray, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.PLoS Medicine, 12(3):e1001779, 2015

    2015

  8. [8]

    Million Veteran Program: A mega-biobank to study genetic influences on health and disease

    John Michael Gaziano, John Concato, Mary Brophy, Louis Fiore, Saiju Pyarajan, James Breeling, Stacey Whitbourne, Jennifer Deen, Colleen Shannon, Donald Humphries, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. Journal of Clinical Epidemiology, 70:214–223, 2016

    2016

Show all 109 references
  1. [9]

    All of Us

    All of Us Research Program Investigators. The “All of Us” research program.New England Journal of Medicine, 381(7):668–676, 2019

    2019

  2. [10]

    FinnGen provides genetic insights from a well-phenotyped isolated population.Nature, 613(7944):508–518, 2023

    Mitja I Kurki, Juha Karjalainen, Priit Palta, Timo P Sipilä, Kati Kristiansson, Kati M Donner, Mary P Reeve, Hannele Laivuori, Mervi Aavikko, Mari A Kaunisto, et al. FinnGen provides genetic insights from a well-phenotyped isolated population.Nature, 613(7944):508–518, 2023

    2023

  3. [11]

    Toward the 1000 dollars human genome.Pharmacogenomics, 6(4):373–382, 2005

    Simon T Bennett, Colin Barnes, Anthony Cox, Lisa Davies, and Clive Brown. Toward the 1000 dollars human genome.Pharmacogenomics, 6(4):373–382, 2005

    2005

  4. [12]

    DNA sequencing technologies: 2006–2016.Nature Protocols, 12(2): 213–218, 2017

    Elaine R Mardis. DNA sequencing technologies: 2006–2016.Nature Protocols, 12(2): 213–218, 2017

    2006

  5. [13]

    The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)

    Jacqueline MacArthur, Emily Bowler, Maria Cerezo, Laurent Gil, Peggy Hall, Emma Hastings, Heather Junkins, Aoife McMahon, Annalisa Milano, Joannella Morales, et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Research, 4...

    2017

  6. [14]

    UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits.MedRxiv, pages 2022–06, 2022

    Deborah J Thompson, Daniel Wells, Saskia Selzam, Iliana Peneva, Rachel Moore, Kevin Sharp, William A Tarran, Edward J Beard, Fernando Riveros-Mckay, Carla Giner- Delgado, et al. UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and...

    2022

  7. [15]

    From GWAS to function: using functional genomics to identify the mechanisms underlying complex diseases.Frontiers in Genetics, 11:424, 2020

    Eddie Cano-Gamez and Gosia Trynka. From GWAS to function: using functional genomics to identify the mechanisms underlying complex diseases.Frontiers in Genetics, 11:424, 2020

    2020

  8. [16]

    The personal and clinical utility of polygenic risk scores.Nature Reviews Genetics, 19(9):581–590, 2018

    Ali Torkamani, Nathan E Wineinger, and Eric J Topol. The personal and clinical utility of polygenic risk scores.Nature Reviews Genetics, 19(9):581–590, 2018

    2018

  9. [17]

    Polygenic risk scores in the clinic: translating risk into action.Human Genetics and Genomics Advances, 2(4), 2021

    Anna CF Lewis, Robert C Green, and Jason L Vassy. Polygenic risk scores in the clinic: translating risk into action.Human Genetics and Genomics Advances, 2(4), 2021

    2021

  10. [18]

    The support of human genetic evidence for approved drug indications.Nature Genetics, 47 (8):856–860, 2015

    Matthew R Nelson, Hannah Tipney, Jeffery L Painter, Judong Shen, Paola Nicoletti, Yufeng Shen, Aris Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang, et al. The support of human genetic evidence for approved drug indications.Nature Genetics, 47 (8):856–860, 2015. 19 January...

    2015

  11. [19]

    Emily A King, J Wade Davis, and Jacob F Degner. Are drug targets with genetic support twice as likely to be approved? revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.PLoS Genetics, 15 (12):e1008489, 2019

    2019

  12. [20]

    GeneDisco: A Benchmark for Experimental Design in Drug Discovery

    Arash Mehrjou, Ashkan Soleymani, Andrew Jesson, Pascal Notin, Yarin Gal, Stefan Bauer, and Patrick Schwab. GeneDisco: A Benchmark for Experimental Design in Drug Discovery. InInternational Conference on Learning Representations, 2022

    2022

  13. [21]

    DiscoBAX discovery of optimal intervention sets in genomic experiment design

    Clare Lyle, Arash Mehrjou, Pascal Notin, Andrew Jesson, Stefan Bauer, Yarin Gal, and Patrick Schwab. DiscoBAX discovery of optimal intervention sets in genomic experiment design. In Andreas Krause, Emma Brunskill, Kyunghyun Cho, Barbara Engelhardt, Sivan Sabato, and Jonathan S...

    2023

  14. [22]

    Refining the impact of genetic evidence on clinical success.medRxiv, pages 2023–06, 2023

    Eric Vallabh Minikel, Jeffery L Painter, Coco Chengliang Dong, and Matthew R Nelson. Refining the impact of genetic evidence on clinical success.medRxiv, pages 2023–06, 2023

    2023

  15. [23]

    Genome-wide association studies.Nature Reviews Methods Primers, 1(1):59, 2021

    Emil Uffelmann, Qin Qin Huang, Nchangwi Syntia Munung, Jantina De Vries, Yukinori Okada, Alicia R Martin, Hilary C Martin, Tuuli Lappalainen, and Danielle Posthuma. Genome-wide association studies.Nature Reviews Methods Primers, 1(1):59, 2021

    2021

  16. [24]

    Polygenic risk scores: from research tools to clinical instruments

    Cathryn M Lewis and Evangelos Vassos. Polygenic risk scores: from research tools to clinical instruments. Genome Medicine, 12(1):1–11, 2020

    2020

  17. [25]

    A global reference for human genetic variation

    1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature, 526(7571):68, 2015

    2015

  18. [26]

    Accounting for linkage disequilibrium in association analysis of diverse populations.Genetic Epidemiology, 38 (3):265–273, 2014

    Bashira A Charles, Daniel Shriner, and Charles N Rotimi. Accounting for linkage disequilibrium in association analysis of diverse populations.Genetic Epidemiology, 38 (3):265–273, 2014

    2014

  19. [27]

    Analysis of polygenic risk score usage and performance in diverse human populations

    Laramie Duncan, H Shen, B Gelaye, J Meijsen, K Ressler, M Feldman, R Peterson, and Ben Domingue. Analysis of polygenic risk score usage and performance in diverse human populations. Nature Communications, 10(1):3328, 2019

    2019

  20. [28]

    Improving polygenic prediction in ancestrally diverse populations.Nature Genetics, 54(5):573–580, 2022

    Yunfeng Ruan, Yen-Feng Lin, Yen-Chen Anne Feng, Chia-Yen Chen, Max Lam, Zhenglin Guo, Lin He, Akira Sawa, Alicia R Martin, et al. Improving polygenic prediction in ancestrally diverse populations.Nature Genetics, 54(5):573–580, 2022

    2022

  21. [29]

    The post-GWAS era: from association to function

    Michael D Gallagher and Alice S Chen-Plotkin. The post-GWAS era: from association to function. American Journal of Human Genetics, 102(5):717–730, 2018

    2018

  22. [30]

    Multiple personal genomes await.Nature, 464(7289):676–677, 2010

    J Craig Venter. Multiple personal genomes await.Nature, 464(7289):676–677, 2010

    2010

  23. [31]

    DeepNull models non-linear covariate effects to improve phenotypic prediction and association power

    Zachary R McCaw, Thomas Colthurst, Taedong Yun, Nicholas A Furlotte, Andrew Carroll, Babak Alipanahi, Cory Y McLean, and Farhad Hormozdiari. DeepNull models non-linear covariate effects to improve phenotypic prediction and association power. Nature Communications, 13(1):241, 2022

    2022

  24. [32]

    Single Nucleotide Polymorphism relevance learning with Random Forests for Type 2 diabetes risk prediction.Artificial Intelligence in Medicine, 85:43–49, 2018

    Beatriz López, Ferran Torrent-Fontbona, Ramón Viñas, and José Manuel Fernández- Real. Single Nucleotide Polymorphism relevance learning with Random Forests for Type 2 diabetes risk prediction.Artificial Intelligence in Medicine, 85:43–49, 2018. 20 January 15, 2025 prepublication draft

    2018

  25. [33]

    Non-linear machine learning models incorporating SNPs and PRS improve polygenic prediction in diverse human populations.Communications Biology, 5(1):856, 2022

    Michael Elgart, Genevieve Lyons, Santiago Romero-Brufau, Nuzulul Kurniansyah, Jennifer A Brody, Xiuqing Guo, Henry J Lin, Laura Raffield, Yan Gao, Han Chen, et al. Non-linear machine learning models incorporating SNPs and PRS improve polygenic prediction in diverse human popul...

    2022

  26. [34]

    Genome wide association neural networks (GWANN) identify novel genes linked to family history of Alzheimer’s disease in the UK Biobank.medRxiv, pages 2022–06, 2022

    Upamanyu Ghose, William Sproviero, Laura Winchester, Marco Fernandes, Danielle Newby, Brittany S Ulm, Liu Shi, Qiang Liu, Cassandra Adams, Ashwag Albukhari, et al. Genome wide association neural networks (GWANN) identify novel genes linked to family history of Alzheimer’s dise...

    2022

  27. [35]

    Genome-wide prediction of disease variant effects with a deep protein language model

    Nadav Brandes, Grant Goldman, Charlotte H Wang, Chun Jimmie Ye, and Vasilis Ntranos. Genome-wide prediction of disease variant effects with a deep protein language model. Nature Genetics, pages 1–11, 2023

    2023

  28. [36]

    Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences

    Alexander Rives, Joshua Meier, Tom Sercu, Siddharth Goyal, Zeming Lin, Jason Liu, Demi Guo, Myle Ott, C Lawrence Zitnick, Jerry Ma, et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proceedings of the National ...

    2021

  29. [37]

    Disease variant prediction with deep generative models of evolutionary data.Nature, 599(7883):91–95, 2021

    Jonathan Frazer, Pascal Notin, Mafalda Dias, Aidan Gomez, Joseph K Min, Kelly Brock, Yarin Gal, and Debora S Marks. Disease variant prediction with deep generative models of evolutionary data.Nature, 599(7883):91–95, 2021

    2021

  30. [38]

    Accurate proteome-wide missense variant effect prediction with AlphaMissense.Science, page eadg7492, 2023

    Jun Cheng, Guido Novati, Joshua Pan, Clare Bycroft, Akvil˙ e Žemgulyt˙ e, Taylor Ap- plebaum, Alexander Pritzel, Lai Hong Wong, Michal Zielinski, Tobias Sargeant, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense.Science, page eadg7492, 2023

    2023

  31. [39]

    Exome sequencing and analysis of 454,787 UK Biobank participants

    Joshua D Backman, Alexander H Li, Anthony Marcketta, Dylan Sun, Joelle Mbatchou, Michael D Kessler, Christian Benner, Daren Liu, Adam E Locke, Suganthi Balasub- ramanian, et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature, 599(7886):628–634, 2021

    2021

  32. [40]

    Annotating and prioritizing human non-coding variants with RegulomeDB v

    Shengcheng Dong, Nanxiang Zhao, Emma Spragins, Meenakshi S Kagda, Mingjie Li, Pedro Assis, Otto Jolanki, Yunhai Luo, J Michael Cherry, Alan P Boyle, et al. Annotating and prioritizing human non-coding variants with RegulomeDB v. 2.Nature Genetics, pages 1–3, 2023

    2023

  33. [41]

    Nucleotide transformer: building and evaluating robust foundation models for human genomics.Nature Methods, pages 1–11, 2024

    Hugo Dalla-Torre, Liam Gonzalez, Javier Mendoza-Revilla, Nicolas Lopez Car- ranza, Adam Henryk Grzywaczewski, Francesco Oteri, Christian Dallago, Evan Trop, Bernardo P de Almeida, Hassan Sirelkhatim, et al. Nucleotide transformer: building and evaluating robust foundation mode...

    2024

  34. [42]

    Sequence modeling and design from molecular to genome scale with evo.Science, 386(6723): eado9336, 2024

    Eric Nguyen, Michael Poli, Matthew G Durrant, Brian Kang, Dhruva Katrekar, David B Li, Liam J Bartie, Armin W Thomas, Samuel H King, Garyk Brixi, et al. Sequence modeling and design from molecular to genome scale with evo.Science, 386(6723): eado9336, 2024

    2024

  35. [43]

    Basset: learning the regulatory code of the accessible genome with deep convolutional neural networks.Genome Research, 26(7):990–999, 2016

    David R Kelley, Jasper Snoek, and John L Rinn. Basset: learning the regulatory code of the accessible genome with deep convolutional neural networks.Genome Research, 26(7):990–999, 2016. 21 January 15, 2025 prepublication draft

    2016

  36. [44]

    Sequential regulatory activity prediction across chromosomes with convolutional neural networks.Genome Research, 28(5):739–750, 2018

    David R Kelley, Yakir A Reshef, Maxwell Bileschi, David Belanger, Cory Y McLean, and Jasper Snoek. Sequential regulatory activity prediction across chromosomes with convolutional neural networks.Genome Research, 28(5):739–750, 2018

    2018

  37. [45]

    Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation

    Johannes Linder, Divyanshi Srivastava, Han Yuan, Vikram Agarwal, and David R Kelley. Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation. bioRxiv, pages 2023–08, 2023

    2023

  38. [46]

    Palmer, Nancy J

    Yanyu Liang, Milton Pividori, Ani Manichaikul, Abraham A. Palmer, Nancy J. Cox, Heather E. Wheeler, and Hae Kyung Im. Polygenic transcriptome risk scores (PTRS) can improve portability of polygenic risk scores across ancestries.Genome Biology, 23 (23), 2022

    2022

  39. [47]

    Nonalcoholic fatty liver disease and psoriasis: what a dermatologist needs to know.Journal of Clinical and Aesthetic Dermatology, 8(3):43, 2015

    Ronald Prussick, Lisa Prussick, and Dillon Nussbaum. Nonalcoholic fatty liver disease and psoriasis: what a dermatologist needs to know.Journal of Clinical and Aesthetic Dermatology, 8(3):43, 2015

    2015

  40. [48]

    Complicated acute appendicitis in diabetic patients.American Journal of Surgery, 196 (1):34–39, 2008

    Shih-Hung Tsai, Chin-Wang Hsu, Shin-Chieh Chen, Yen-Yue Lin, and Shi-Jye Chu. Complicated acute appendicitis in diabetic patients.American Journal of Surgery, 196 (1):34–39, 2008

    2008

  41. [49]

    Diabetes is associated with perforated appendicitis: evidence from a population-based study

    Po-Li Wei, Herng-Ching Lin, Li-Ting Kao, Yi-Hua Chen, and Cha-Ze Lee. Diabetes is associated with perforated appendicitis: evidence from a population-based study. American Journal of Surgery, 212(4):735–739, 2016

    2016

  42. [50]

    Estimating the causal tissues for complex traits and diseases.Nature genetics, 49(12):1676–1683, 2017

    Halit Ongen, Andrew A Brown, Olivier Delaneau, Nikolaos I Panousis, Alexandra C Nica, GTEx Consortium, and Emmanouil T Dermitzakis. Estimating the causal tissues for complex traits and diseases.Nature genetics, 49(12):1676–1683, 2017

    2017

  43. [51]

    Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types.Nature genetics, 50(4):621–629, 2018

    Hilary K Finucane, Yakir A Reshef, Verneri Anttila, Kamil Slowikowski, Alexander Gusev, Andrea Byrnes, Steven Gazal, Po-Ru Loh, Caleb Lareau, Noam Shoresh, et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types.Nature ...

    2018

  44. [52]

    Genetic mapping of cell type specificity for complex traits

    Kyoko Watanabe, Maša Umićević Mirkov, Christiaan A de Leeuw, Martijn P van den Heuvel, and Danielle Posthuma. Genetic mapping of cell type specificity for complex traits. Nature communications, 10(1):3222, 2019

    2019

  45. [53]

    Identifying disease- critical cell types and cellular processes by integrating single-cell rna-sequencing and human genetics.Nature genetics, 54(10):1479–1492, 2022

    Karthik A Jagadeesh, Kushal K Dey, Daniel T Montoro, Rahul Mohan, Steven Gazal, Jesse M Engreitz, Ramnik J Xavier, Alkes L Price, and Aviv Regev. Identifying disease- critical cell types and cellular processes by integrating single-cell rna-sequencing and human genetics.Nature...

    2022

  46. [54]

    Modeling tissue co- regulation estimates tissue-specific contributions to disease.Nature genetics, 55(9): 1503–1511, 2023

    Tiffany Amariuta, Katherine Siewert-Rocks, and Alkes L Price. Modeling tissue co- regulation estimates tissue-specific contributions to disease.Nature genetics, 55(9): 1503–1511, 2023

    2023

  47. [55]

    Cranial optic nerve involvements in patients with severe COPD.Respirology, 10(5): 666–672, 2005

    Cengiz Özge, Aynur Özge, Ayça Yilmaz, Deniz E Yalçinkaya, and Mukadder Calikoğlu. Cranial optic nerve involvements in patients with severe COPD.Respirology, 10(5): 666–672, 2005

    2005

  48. [56]

    Correlation between optic nerve involvement and chronic obstructive pulmonary disease.Clinical Ophthalmology, pages 271–275, 2015

    Haleh Mikaeili, Mohammad Yazdchi, Shiva Solahaye Kahnamouii, Elyar Sadeghi- Hokmabadi, and Reshad Mirnour. Correlation between optic nerve involvement and chronic obstructive pulmonary disease.Clinical Ophthalmology, pages 271–275, 2015. 22 January 15, 2025 prepublication draft

    2015

  49. [57]

    Polygenic scores via penalized regression on summary statistics

    Timothy Shin Heng Mak, Robert Milan Porsch, Shing Wan Choi, Xueya Zhou, and Pak Chung Sham. Polygenic scores via penalized regression on summary statistics. Genetic Epidemiology, 41(6):469–480, 2017

    2017

  50. [58]

    Ldpred2: better, faster, stronger

    Florian Privé, Julyan Arbel, and Bjarni J Vilhjálmsson. Ldpred2: better, faster, stronger. Bioinformatics, 36(22-23):5424–5431, 2020

    2020

  51. [59]

    Ivana Semova, Amy E Levenson, Joanna Krawczyk, Kevin Bullock, Kathryn A Williams, R Paul Wadwa, Amy S Shah, Philip R Khoury, Thomas R Kimball, Elaine M Urbina, et al. Type 1 diabetes is associated with an increase in cholesterol absorption markers but a decrease in cholesterol...

    2019

  52. [60]

    UMAP: Uniform manifold approx- imation and projection for dimension reduction

    Leland McInnes, John Healy, and James Melville. UMAP: Uniform manifold approx- imation and projection for dimension reduction. arXiv preprint arXiv:1802.03426, 2018

    2018 arXiv

  53. [61]

    Improving genetic risk prediction across diverse population by disentangling ancestry representations.Communications Biology, 6(1):964, 2023

    Prashnna K Gyawali, Yann Le Guen, Xiaoxia Liu, Michael E Belloy, Hua Tang, James Zou, and Zihuai He. Improving genetic risk prediction across diverse population by disentangling ancestry representations.Communications Biology, 6(1):964, 2023

    2023

  54. [62]

    New insights into the genetic etiology of Alzheimer’s disease and related dementias

    Céline Bellenguez, Fahri Küçükali, Iris E Jansen, Luca Kleineidam, Sonia Moreno-Grau, Najaf Amin, Adam C Naj, Rafael Campos-Martin, Benjamin Grenier-Boley, Victor Andrade, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nature Geneti...

    2022

  55. [63]

    A saturated map of common genetic variants associated with human height.Nature, 610(7933):704–712, 2022

    Loïc Yengo, Sailaja Vedantam, Eirini Marouli, Julia Sidorenko, Eric Bartell, Saori Sakaue, Marielisa Graff, Anders U Eliasen, Yunxuan Jiang, Sridharan Raghavan, et al. A saturated map of common genetic variants associated with human height.Nature, 610(7933):704–712, 2022

    2022

  56. [64]

    How far are we from personalized gene expression prediction using sequence-to-expression deep neural networks? bioRxiv, pages 2023–03, 2023

    Alexander Sasse, Bernard Ng, Anna Spiro, Shinya Tasaki, David A Bennett, Christopher Gaiteri, Philip L De Jager, Maria Chikina, and Sara Mostafavi. How far are we from personalized gene expression prediction using sequence-to-expression deep neural networks? bioRxiv, pages 202...

    2023

  57. [65]

    Vinod Kumar Chauhan, Lei Clifton, Achille Salaün, Huiqi Yvonne Lu, Kim Branson, Patrick Schwab, Gaurav Nigam, and David A. Clifton. Sample selection bias in machine learning for healthcare.arXiv preprint arXiv:2405.07841, 2024

    2024 arXiv

  58. [66]

    Comparison of sociodemographic and health- related characteristics of uk biobank participants with those of the general population

    Anna Fry, Thomas J Littlejohns, Cathie Sudlow, Nicola Doherty, Ligia Adamska, Tim Sprosen, Rory Collins, and Naomi E Allen. Comparison of sociodemographic and health- related characteristics of uk biobank participants with those of the general population. American Journal of E...

    2017

  59. [67]

    Participation bias in the UK Biobank distorts genetic associations and downstream analyses.Nature Human Behaviour, pages 1–12, 2023

    Tabea Schoeler, Doug Speed, Eleonora Porcu, Nicola Pirastu, Jean-Baptiste Pingault, and Zoltán Kutalik. Participation bias in the UK Biobank distorts genetic associations and downstream analyses.Nature Human Behaviour, pages 1–12, 2023

    2023

  60. [68]

    GLU variants improve transformer.arXiv preprint arXiv:2002.05202, 2020

    Noam Shazeer. GLU variants improve transformer.arXiv preprint arXiv:2002.05202, 2020

    2002 arXiv

  61. [69]

    A chronological map of 308 23 January 15, 2025 prepublication draft physical and mental health conditions from 4 million individuals in the english national health service

    Valerie Kuan, Spiros Denaxas, Arturo Gonzalez-Izquierdo, Kenan Direk, Osman Bhatti, Shanaz Husain, Shailen Sutaria, Melanie Hingorani, Dorothea Nitsch, Constantinos A Parisinos, R Thomas Lumbers, Rohini Mathur, Reecha Sofat, Juan P Casas, Ian C K Wong, Harry Hemingway, and Aro...

    2025

  62. [70]

    Halldorsson, Hannes P

    Bjarni V. Halldorsson, Hannes P. Eggertsson, Kristjan H. S. Moore, Hannes Hauswedell, Ogmundur Eiriksson, Magnus O. Ulfarsson, Gunnar Palsson, Marteinn T. Hardarson, Asmundur Oddsson, Brynjar O. Jensson, et al. The sequences of 150,119 genomes in the UK Biobank.Nature, 607(792...

    2022

  63. [71]

    On the stratification of multi-label data.Machine Learning and Knowledge Discovery in Databases, pages 145–158, 2011

    Konstantinos Sechidis, Grigorios Tsoumakas, and Ioannis Vlahavas. On the stratification of multi-label data.Machine Learning and Knowledge Discovery in Databases, pages 145–158, 2011

    2011

  64. [72]

    A Network Perspective on Stratification of Multi-Label Data

    Piotr Szymański and Tomasz Kajdanowicz. A Network Perspective on Stratification of Multi-Label Data. In Luís Torgo, Bartosz Krawczyk, Paula Branco, and Nuno Moniz, editors, Proceedings of the First International Workshop on Learning with Imbalanced Domains: Theory and Applicat...

    2017

  65. [73]

    Pytorch: An imperative style, high-performance deep learning library

    Adam Paszke, Sam Gross, Francisco Massa, Adam Lerer, James Bradbury, Gregory Chanan, Trevor Killeen, Zeming Lin, Natalia Gimelshein, Luca Antiga, et al. Pytorch: An imperative style, high-performance deep learning library. Advances in Neural Information Processing Systems, 32, 2019

    2019

  66. [74]

    Xiangning Chen, Chen Liang, Da Huang, Esteban Real, Kaiyuan Wang, Yao Liu, Hieu Pham, Xuanyi Dong, Thang Luong, Cho-Jui Hsieh, Yifeng Lu, and Quoc V. Le. Symbolic discovery of optimization algorithms.arXiv preprint arXiv:2302.06675, 2023

    2023 arXiv

  67. [75]

    Decoupled weight decay regularization.arXiv preprint arXiv:1711.05101, 2017

    Ilya Loshchilov and Frank Hutter. Decoupled weight decay regularization.arXiv preprint arXiv:1711.05101, 2017

    2017 arXiv

  68. [76]

    Overview of statistical methods for genome-wide association studies (GWAS)

    Ben Hayes. Overview of statistical methods for genome-wide association studies (GWAS). Genome-wide Association Studies and Genomic Prediction, pages 149–169, 2013

    2013

  69. [77]

    Hail Team. Hail. https://github.com/hail-is/hail

  70. [78]

    Computationally efficient whole-genome regression for quantitative and binary traits.Nature genetics, 53(7):1097–1103, 2021

    Joelle Mbatchou, Leland Barnard, Joshua Backman, Anthony Marcketta, Jack A Kosmicki, Andrey Ziyatdinov, Christian Benner, Colm O’Dushlaine, Mathew Barber, Boris Boutkov, et al. Computationally efficient whole-genome regression for quantitative and binary traits.Nature genetics...

    2021

  71. [79]

    PLINK: a tool set for whole-genome association and population-based linkage analyses

    Shaun Purcell, Benjamin Neale, Kathe Todd-Brown, Lori Thomas, Manuel AR Ferreira, David Bender, Julian Maller, Pamela Sklar, Paul IW De Bakker, Mark J Daly, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human G...

    2007

  72. [80]

    Florian Privé, Hugues Aschard, Andrey Ziyatdinov, and Michael G.B. Blum. Efficient analysis of large-scale genome-wide data with two R packages: bigstatsr and bigsnpr. Bioinformatics, 34(16):2781–2787, 2018. doi: 10.1093/bioinformatics/bty185. URL https://doi.org/10.1093/bioin...

    2018 doi

  73. [81]

    Density-based clustering based on hierarchical density estimates

    Ricardo JGB Campello, Davoud Moulavi, and Jörg Sander. Density-based clustering based on hierarchical density estimates. In Pacific-asia conference on Knowledge Discovery and Data mining, pages 160–172. Springer, 2013. 24 January 15, 2025 prepublication draft

    2013

  74. [82]

    Scikit-learn: Machine learning in python.Journal of Machine Learning Research, 12:2825–2830, 2011

    Fabian Pedregosa, Gaël Varoquaux, Alexandre Gramfort, Vincent Michel, Bertrand Thirion, Olivier Grisel, Mathieu Blondel, Peter Prettenhofer, Ron Weiss, Vincent Dubourg, et al. Scikit-learn: Machine learning in python.Journal of Machine Learning Research, 12:2825–2830, 2011

    2011

  75. [83]

    Deep inside convolutional networks: Visualising image classification models and saliency maps.arXiv preprint arXiv:1312.6034, 2013

    Karen Simonyan, Andrea Vedaldi, and Andrew Zisserman. Deep inside convolutional networks: Visualising image classification models and saliency maps.arXiv preprint arXiv:1312.6034, 2013

    2013 arXiv

  76. [84]

    Captum: A unified and generic model interpretability library for pytorch.arXiv preprint arXiv:2009.07896, 2020

    Narine Kokhlikyan, Vivek Miglani, Miguel Martin, Edward Wang, Bilal Alsallakh, Jonathan Reynolds, Alexander Melnikov, Natalia Kliushkina, Carlos Araya, Siqi Yan, et al. Captum: A unified and generic model interpretability library for pytorch.arXiv preprint arXiv:2009.07896, 2020

    2009 arXiv

  77. [85]

    Ella AM van der Voort, Edith M Koehler, Emmilia A Dowlatshahi, Albert Hofman, Bruno H Stricker, Harry LA Janssen, Jeoffrey NL Schouten, and Tamar Nijsten. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results fro...

    2014

  78. [86]

    Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.Journal of Hepatology, 51(4):778–786, 2009

    Luca Miele, Selenia Vallone, Consuelo Cefalo, Giuseppe La Torre, Carmine Di Stasi, Fabio M Vecchio, Magda D’Agostino, Maria L Gabrieli, Vittoria Vero, Marco Biolato, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic p...

    2009

  79. [87]

    Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease.Clinical and Experimental Dermatology, 40(7):722–727, 2015

    R Abedini, M Salehi, V Lajevardi, and S Beygi. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease.Clinical and Experimental Dermatology, 40(7):722–727, 2015

    2015

  80. [88]

    Selenium in chronic liver disease.Journal of Hepatology, 14(2-3):176–182, 1992

    PJ Thuluvath and DR Triger. Selenium in chronic liver disease.Journal of Hepatology, 14(2-3):176–182, 1992

    1992

  81. [89]

    Treatment with spexin mitigates diet-induced hepatic steatosis in vivo and in vitro through activation of galanin receptor

    Mengyuan Wang, Ziyue Zhu, Yue Kan, Mei Yu, Wancheng Guo, Mengxian Ju, Junjun Wang, Shuxin Yi, Shiyu Han, Wenbin Shang, et al. Treatment with spexin mitigates diet-induced hepatic steatosis in vivo and in vitro through activation of galanin receptor

  82. [90]

    Molecular and Cellular Endocrinology, 552:111688, 2022

    2022

  83. [91]

    Effects of cyp7a1 overexpression on cholesterol and bile acid homeostasis.American Journal of Physiology-Gastrointestinal and Liver Physiology, 281(4):G878–G889, 2001

    WM Pandak, C Schwarz, PB Hylemon, D Mallonee, K Valerie, DM Heuman, RA Fisher, Kaye Redford, and ZR Vlahcevic. Effects of cyp7a1 overexpression on cholesterol and bile acid homeostasis.American Journal of Physiology-Gastrointestinal and Liver Physiology, 281(4):G878–G889, 2001

    2001

  84. [92]

    Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity.Journal of Biological Chemistry, 287(3):1861–1873, 2012

    Tiangang Li, Jessica M Francl, Shannon Boehme, Adrian Ochoa, Youcai Zhang, Curtis D Klaassen, Sandra K Erickson, and John YL Chiang. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity.Journal of Biological Chemistry, 287(3)...

    2012

  85. [93]

    Increased risk of open-angle glaucoma in non- smoking women with obstructive pattern of spirometric tests.Scientific Reports, 12(1): 16915, 2022

    Jihei Sara Lee, Yong Joon Kim, Sung Soo Kim, Sungeun Park, Wungrak Choi, Hy- oung Won Bae, and Chan Yun Kim. Increased risk of open-angle glaucoma in non- smoking women with obstructive pattern of spirometric tests.Scientific Reports, 12(1): 16915, 2022

    2022

  86. [94]

    Systemic diseases and their association with open-angle glaucoma in the population of stockholm.International Ophthalmology, pages 1–9, 2022

    Per Wändell, Axel C Carlsson, and Gunnar Ljunggren. Systemic diseases and their association with open-angle glaucoma in the population of stockholm.International Ophthalmology, pages 1–9, 2022. 25 January 15, 2025 prepublication draft

    2022

  87. [95]

    Mendelian genes in primary open angle glaucoma.Experimental Eye Research, 186:107702, 2019

    Nathan C Sears, Erin A Boese, Mathew A Miller, and John H Fingert. Mendelian genes in primary open angle glaucoma.Experimental Eye Research, 186:107702, 2019

    2019

  88. [96]

    Identification of optn p.(asn51thr): A novel pathogenic variant in primary open-angle glaucoma

    Yukihiro Shiga, Kazuki Hashimoto, Kosuke Fujita, Shigeto Maekawa, Kota Sato, Shin- taroh Kubo, Kazuhide Kawase, Kana Tokumo, Yoshiaki Kiuchi, Sotaro Mori, et al. Identification of optn p.(asn51thr): A novel pathogenic variant in primary open-angle glaucoma. Genetics in Medicin...

    2024

  89. [97]

    Causalbench: A large-scale benchmark for network inference from single-cell perturbation data

    Mathieu Chevalley, Yusuf Roohani, Arash Mehrjou, Jure Leskovec, and Patrick Schwab. Causalbench: A large-scale benchmark for network inference from single-cell perturbation data. arXiv preprint arXiv:2210.17283, 2022

    2022 arXiv

  90. [98]

    Deriving Causal Order from Single- Variable Interventions: Guarantees & Algorithm

    Arash Mehrjou Mathieu Chevalley, Patrick Schwab. Deriving Causal Order from Single- Variable Interventions: Guarantees & Algorithm. arXiv preprint arXiv:2405.18314, 2024

    2024 arXiv

  91. [99]

    Systematic immune cell dysregulation and molecular subtypes revealed by single-cell rna-seq of subjects with type 1 diabetes

    Mohammad Amin Honardoost, Andreas Adinatha, Florian Schmidt, Bobby Ranjan, Maryam Ghaeidamini, Nirmala Arul Rayan, Michelle Gek Liang Lim, Ignasius Joanito, Quy Xiao Xuan Lin, Deepa Rajagopalan, et al. Systematic immune cell dysregulation and molecular subtypes revealed by sin...

    2024

  92. [100]

    Devel- opmental cell programs are co-opted in inflammatory skin disease.Science, 371(6527): eaba6500, 2021

    Gary Reynolds, Peter Vegh, James Fletcher, Elizabeth FM Poyner, Emily Stephenson, Issac Goh, Rachel A Botting, Ni Huang, Bayanne Olabi, Anna Dubois, et al. Devel- opmental cell programs are co-opted in inflammatory skin disease.Science, 371(6527): eaba6500, 2021

    2021

  93. [101]

    High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.Cancer cell, 40(12):1503–1520, 2022

    Stefan Salcher, Gregor Sturm, Lena Horvath, Gerold Untergasser, Christiane Kuempers, Georgios Fotakis, Elisa Panizzolo, Agnieszka Martowicz, Manuel Trebo, Georg Pall, et al. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in no...

    2022

  94. [102]

    Axiomatic attribution for deep networks

    Mukund Sundararajan, Ankur Taly, and Qiqi Yan. Axiomatic attribution for deep networks. InInternational Conference on Machine Learning, pages 3319–3328. PMLR, 2017

    2017

  95. [103]

    Abnormal regulation of fibronectin production by fibroblasts in psoriasis.British Journal of Dermatology, 174(3):533–541, 2016

    Barbara Gubán, Krisztina Vas, Zsanett Balog, Máté Manczinger, Attila Bebes, Gergely Groma, Márta Széll, Lajos Kemény, and Zsuzsanna Bata-Csörgő. Abnormal regulation of fibronectin production by fibroblasts in psoriasis.British Journal of Dermatology, 174(3):533–541, 2016

    2016

  96. [104]

    Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes.Clinics in Dermatology, 25(6):581–588, 2007

    Cristina Albanesi, Ornella De Pità, and Giampiero Girolomoni. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes.Clinics in Dermatology, 25(6):581–588, 2007

    2007

  97. [105]

    Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis

    April W Armstrong, Stephanie V Voyles, Ehrin J Armstrong, Erin N Fuller, and John C Rutledge. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. Journal of Dermatological Science, 63(1):1–9, 2011

    2011

  98. [106]

    The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure

    Bart O Roep. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia, 46:305–321, 2003

    2003

  99. [107]

    B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes.Trends in Endocrinology & Metabolism, 17(4):128–135, 2006

    Pablo A Silveira and Shane T Grey. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes.Trends in Endocrinology & Metabolism, 17(4):128–135, 2006. 26 January 15, 2025 prepublication draft

    2006

  100. [108]

    Petter Höglund, Justine Mintern, Caroline Waltzinger, William Heath, Christophe Benoist, and Diane Mathis. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes.Journal of Experimental Medicine, 189(2):...

    1999

  101. [109]

    Diabetes alters subsets of endothelial progenitor cells that reside in blood, bone marrow, and spleen.American Journal of Physiology-Cell Physiology, 302(6):C892–C901, 2012

    Hidehito Saito, Yasuhiko Yamamoto, and Hiroshi Yamamoto. Diabetes alters subsets of endothelial progenitor cells that reside in blood, bone marrow, and spleen.American Journal of Physiology-Cell Physiology, 302(6):C892–C901, 2012. 27 January 15, 2025 prepublication draft Indiv...

    2012

Pith tools

Reviewed August 10, 2026 · model on record in the stance chip above.